Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial.

Gastroenterology·2026
Same author

Development and Validation of a Large Language Model Case Identification Strategy for Eosinophilic Esophagitis.

Gastro hep advances·2026
Same author

Glucuronidation metabolomic fingerprinting to map host-microbe metabolism.

Nature communications·2026
Same author

Prevalence of inflammatory bowel disease across states: estimates based on claims database.

Inflammatory bowel diseases·2026
Same author

Comparative effectiveness of low versus high dose upadacitinib as maintenance treatment in patients with ulcerative colitis: a real-world cohort study from the United States.

Crohn's & colitis 360·2026
Same author

Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.

Journal of Crohn's & colitis·2026

Related Experiment Video

Updated: Jul 20, 2026

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

Malignancies in inflammatory bowel disease.

Radhika Srinivasan1, James D Lewis

  • 1Division of Gastroenterology, Presbyterian Medical Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. radhika.srinivasan@uphs.upenn.edu

Current Opinion in Gastroenterology
|February 11, 2005
PubMed
Summary

Inflammatory bowel disease (IBD) patients face cancer risks, including pancreatic cancer. Research in 2002 explored dysplasia, medication safety (azathioprine, anti-TNF therapy), and post-surgery risks, with ongoing biomarker development for surveillance.

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Experiment Videos

Last Updated: Jul 20, 2026

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Area of Science:

  • Gastroenterology and Oncology
  • Immunology and Cancer Biology

Background:

  • Inflammatory bowel disease (IBD) is associated with an increased risk of gastrointestinal, hepatobiliary, and non-gastrointestinal cancers.
  • Understanding the natural history, risk factors, and surveillance strategies for malignancy in IBD patients is crucial.

Purpose of the Study:

  • To review studies published in 2002 addressing cancer risk, biology, and natural history in IBD.
  • To synthesize current knowledge on colonic and extracolonic cancers in the context of IBD.

Main Methods:

  • Review of studies published in 2002 concerning IBD and cancer.
  • Analysis of research on dysplasia, medication safety, surgical outcomes, and specific cancer risks (e.g., pancreatic cancer).

Main Results:

  • Conflicting data on the natural history of low-grade dysplasia in ulcerative colitis.
  • Azathioprine showed no increased cancer risk; anti-tumor necrosis factor therapy suggested a potential lymphoma risk.
  • Patients post-total proctocolectomy and ileoanal pouch anastomosis retain a small bowel cancer risk.
  • IBD patients with primary sclerosing cholangitis demonstrated an increased risk of pancreatic cancer.

Conclusions:

  • Ongoing research in 2002 provided insights into IBD-associated cancer risks, including specific concerns with anti-TNF therapy and pancreatic cancer in PSC patients.
  • Further long-term studies are needed to clarify lymphoma risks with anti-TNF therapy and the behavior of low-grade dysplasia.
  • Development and clinical application of malignancy biomarkers for IBD surveillance are anticipated.